CN1778323B - 一种治疗心血管疾病的药物滴丸 - Google Patents
一种治疗心血管疾病的药物滴丸 Download PDFInfo
- Publication number
- CN1778323B CN1778323B CN 200410072940 CN200410072940A CN1778323B CN 1778323 B CN1778323 B CN 1778323B CN 200410072940 CN200410072940 CN 200410072940 CN 200410072940 A CN200410072940 A CN 200410072940A CN 1778323 B CN1778323 B CN 1778323B
- Authority
- CN
- China
- Prior art keywords
- film
- ultrafiltration
- chinese medicine
- membrane
- dripping pills
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006187 pill Substances 0.000 title claims abstract description 40
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 5
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 87
- 239000003814 drug Substances 0.000 claims abstract description 45
- 239000007788 liquid Substances 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 23
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 12
- 239000012528 membrane Substances 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 21
- 206010002383 Angina Pectoris Diseases 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 230000000737 periodic effect Effects 0.000 claims description 12
- 229920002492 poly(sulfone) Polymers 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 229920006393 polyether sulfone Polymers 0.000 claims description 10
- 235000015073 liquid stocks Nutrition 0.000 claims description 9
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 9
- 239000011550 stock solution Substances 0.000 claims description 9
- 229920001747 Cellulose diacetate Polymers 0.000 claims description 8
- 239000002033 PVDF binder Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 6
- 229910052756 noble gas Inorganic materials 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 235000002791 Panax Nutrition 0.000 claims description 4
- 241000208343 Panax Species 0.000 claims description 4
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 4
- 244000131316 Panax pseudoginseng Species 0.000 claims description 4
- 239000004695 Polyether sulfone Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 238000000703 high-speed centrifugation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- KXJGSNRAQWDDJT-UHFFFAOYSA-N 1-acetyl-5-bromo-2h-indol-3-one Chemical compound BrC1=CC=C2N(C(=O)C)CC(=O)C2=C1 KXJGSNRAQWDDJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 239000006286 aqueous extract Substances 0.000 claims 1
- 238000011017 operating method Methods 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 238000004140 cleaning Methods 0.000 description 28
- 238000011001 backwashing Methods 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 13
- 230000008859 change Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229940057995 liquid paraffin Drugs 0.000 description 8
- 108090000862 Ion Channels Proteins 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 7
- 239000005708 Sodium hypochlorite Substances 0.000 description 7
- 238000000429 assembly Methods 0.000 description 7
- 230000000712 assembly Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011010 flushing procedure Methods 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 7
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000006793 arrhythmia Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000007718 Stable Angina Diseases 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- -1 nitrous acid ester Chemical class 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008394 flocculating agent Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Landscapes
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410072940 CN1778323B (zh) | 2004-11-26 | 2004-11-26 | 一种治疗心血管疾病的药物滴丸 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410072940 CN1778323B (zh) | 2004-11-26 | 2004-11-26 | 一种治疗心血管疾病的药物滴丸 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1778323A CN1778323A (zh) | 2006-05-31 |
CN1778323B true CN1778323B (zh) | 2010-05-12 |
Family
ID=36768860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410072940 Active CN1778323B (zh) | 2004-11-26 | 2004-11-26 | 一种治疗心血管疾病的药物滴丸 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1778323B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101085070B (zh) * | 2006-06-08 | 2011-09-21 | 天津天士力制药股份有限公司 | 含有三七、山楂的中药组合物及其制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1348815A (zh) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | 一种预防和治疗冠心病心绞痛的药物及其制备方法和其它用途 |
CN1421241A (zh) * | 2002-12-23 | 2003-06-04 | 北京采瑞医药有限公司 | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 |
CN1422664A (zh) * | 2002-12-23 | 2003-06-11 | 北京采瑞医药有限公司 | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 |
-
2004
- 2004-11-26 CN CN 200410072940 patent/CN1778323B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1348815A (zh) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | 一种预防和治疗冠心病心绞痛的药物及其制备方法和其它用途 |
CN1421241A (zh) * | 2002-12-23 | 2003-06-04 | 北京采瑞医药有限公司 | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 |
CN1422664A (zh) * | 2002-12-23 | 2003-06-11 | 北京采瑞医药有限公司 | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
冉军.试论活血化瘀法的临床应用.厂矿医药卫生14 3.1998,14(3),188-189. |
冉军.试论活血化瘀法的临床应用.厂矿医药卫生14 3.1998,14(3),188-189. * |
Also Published As
Publication number | Publication date |
---|---|
CN1778323A (zh) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101085071B (zh) | 含有丹参、山楂的中药组合物及其制剂 | |
CN101085012B (zh) | 一种含红花治疗心血管疾病的组合物及其制剂 | |
CN101085024A (zh) | 含有丹参、银杏叶的中药组合物及其制剂 | |
CN1778336B (zh) | 一种复方丹参滴丸的制备方法 | |
CN1778323B (zh) | 一种治疗心血管疾病的药物滴丸 | |
CN101085064B (zh) | 一种含赤芍治疗心血管疾病的组合物及其制剂 | |
CN101085027B (zh) | 含有丹参、葛根的中药组合物及其制剂 | |
CN1778340B (zh) | 一种治疗冠心病心绞痛的中药组合物 | |
CN101084996B (zh) | 含有丹参的中药组合物及其制剂 | |
CN101085134A (zh) | 一种含血竭治疗心血管疾病的组合物及其制剂 | |
CN1751704B (zh) | 一种含丹参的中药注射剂 | |
CN1778335B (zh) | 一种治疗冠心病心绞痛的中药 | |
CN1785250B (zh) | 一种含丹参的中药粉针剂 | |
CN1778343B (zh) | 一种治疗冠心病的药物滴丸 | |
CN1778353B (zh) | 一种治疗心血管疾病的中药滴丸 | |
CN101085010A (zh) | 一种含盐肤木治疗心血管疾病的组合物及其制剂 | |
CN101085011A (zh) | 一种含延胡索治疗心血管疾病的组合物及其制剂 | |
CN1778334B (zh) | 治疗冠心病心绞痛的中药滴丸 | |
CN1778333B (zh) | 治疗冠心病心绞痛的中药 | |
CN1778337B (zh) | 一种复方丹参片的制备方法 | |
CN1778339B (zh) | 治疗冠心病心绞痛的药物滴丸 | |
CN1778327B (zh) | 治疗心血管疾病的药物滴丸 | |
CN1778345B (zh) | 治疗冠心病的中药滴丸 | |
CN1778354B (zh) | 一种治疗冠心病心绞痛的中药滴丸 | |
CN1751675B (zh) | 一种中药复方注射剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tasly Pharmaceutical Group Co., Ltd. |